{"id":4129,"date":"2026-11-06T09:00:00","date_gmt":"2026-11-06T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4129"},"modified":"2026-11-07T16:07:52","modified_gmt":"2026-11-07T20:07:52","slug":"oral-il23-receptor-blocker-meets-phase-3-psoriasis-endpoints","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4129","title":{"rendered":"Oral IL23 Receptor Blocker Meets Phase 3 Psoriasis Endpoints"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Johnson_and_Johnson_Therapeutic_Indications-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4141\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Johnson_and_Johnson_Therapeutic_Indications-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Johnson_and_Johnson_Therapeutic_Indications-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Johnson_and_Johnson_Therapeutic_Indications-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Johnson_and_Johnson_Therapeutic_Indications-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Johnson_and_Johnson_Therapeutic_Indications.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Johnson &amp; Johnson Innovative Medicine<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Phase 3 data disclosure (ICONIC-ASCEND)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Oral peptide<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Icotrokinra<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>IL-23 receptor<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Moderate-to-severe plaque psoriasis<\/p>\n<h4>Summary<\/h4>\n<p>Johnson &amp; Johnson disclosed November 6 Phase 3 ICONIC-ASCEND data for oral IL-23 receptor antagonist icotrokinra in moderate-to-severe plaque psoriasis. Week-16 PASI 90 was 55.2% versus 3.6% on placebo and IGA 0\/1 was 70.4% versus 9.5%. These are new comparative results, not a regulatory decision.<\/p>\n<p>The company reports noninferiority to ustekinumab and numerically higher clearance in some analyses. In systemic-naive patients at week 28, complete clearance was 48% versus 31% with ustekinumab; this subgroup should not be generalized to all patients. Full adverse-event, multiplicity and durability tables need the underlying presentation.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> convenient oral IL-23 blockade may displace some injectable biologic use if efficacy persists with acceptable long-term safety. The placebo-controlled result supports activity. Counterargument: noninferiority to one older biologic does not prove equivalence to leading IL-23 inhibitors.<\/p>\n<p><strong>Interpretation B:<\/strong> convenience may be the main differentiator rather than maximal skin clearance. Head-to-head efficacy, adherence, safety and payer access would decide.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Plaque psoriasis is a chronic IL-23\/Th17-mediated inflammatory skin disease. Icotrokinra is a once-daily oral peptide that antagonizes the IL-23 receptor and disrupts downstream inflammatory signaling.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>The 17-point week-28 difference is a reported subgroup comparison.<\/li>\n<li>No superiority claim for the full randomized population is established from the disclosed summary.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A material Phase 3 mechanism and format signal, with competitive positioning still dependent on full head-to-head data.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: positive for trial endpoints; uncertain for comparative market displacement. Confidence in Facts: moderate-high for company-reported trial data. Confidence in Interpretation: moderate-low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &#038; Johnson disclosed November 6 Phase 3 ICONIC-ASCEND data for oral IL-23 receptor antagonist icotrokinra in moderate-to-severe plaque psoriasis. Week-16 PASI 90 was 55.2% versus 3.6% on placebo and IGA 0\/1 was 70.4%&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4141,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1402,79,187],"class_list":["post-4129","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-icotrokinra","tag-johnson-johnson","tag-plaque-psoriasis"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4129"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4129\/revisions"}],"predecessor-version":[{"id":4151,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4129\/revisions\/4151"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4141"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}